Dyne Historical Income Statement
| DYN Stock | USD 29.69 0.04 0.13% |
Historical analysis of Dyne Therapeutics income statement accounts such as Selling General Administrative of 29.8 M or Total Revenue of 0.0 can show how well Dyne Therapeutics performed in making a profits. Evaluating Dyne Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Dyne Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Dyne Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Dyne Therapeutics is a good buy for the upcoming year.
Dyne |
About Dyne Income Statement Analysis
Dyne Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Dyne Therapeutics shareholders. The income statement also shows Dyne investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Dyne Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Dyne Therapeutics. It is also known as Dyne Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Dyne Therapeutics income statement and represents the costs associated with goods and services Dyne Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Dyne Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Dyne Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.At this time, Dyne Therapeutics' Total Operating Expenses is very stable compared to the past year. As of the 24th of November 2024, Total Other Income Expense Net is likely to grow to about 6.5 M, while Depreciation And Amortization is likely to drop about 1.6 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 1.1M | 1.7M | 1.7M | 997.5K | Research Development | 121.3M | 142.8M | 210.8M | 221.3M |
Dyne Therapeutics income statement Correlations
Click cells to compare fundamentals
Dyne Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Dyne Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (762K) | 700K | 1.1M | 1.7M | 1.7M | 1.6M | |
| Interest Expense | 290K | 396K | 742K | 2.9M | 2.6M | 2.5M | |
| Selling General Administrative | 2.8M | 13.4M | 28.7M | 28.2M | 31.4M | 29.8M | |
| Gross Profit | (271K) | (700K) | (1.1M) | (3.3M) | (2.5M) | (2.3M) | |
| Other Operating Expenses | 13.8M | 58.6M | 150.0M | 171.0M | 242.2M | 230.1M | |
| Operating Income | (13.8M) | (58.6M) | (150.0M) | (171.0M) | (242.2M) | (230.1M) | |
| Ebit | (13.8M) | (58.6M) | (149.3M) | (171.0M) | (235.1M) | (223.4M) | |
| Ebitda | (14.6M) | (57.9M) | (148.2M) | (169.3M) | (233.5M) | (221.8M) | |
| Cost Of Revenue | 271K | 700K | 1.1M | 3.3M | 2.5M | 2.3M | |
| Total Operating Expenses | 13.8M | 58.6M | 150.0M | 171.0M | 242.2M | 254.3M | |
| Income Before Tax | (14.9M) | (59.4M) | (149.3M) | (168.1M) | (235.9M) | (247.7M) | |
| Total Other Income Expense Net | (1.0M) | (790K) | 734K | 2.9M | 6.2M | 6.5M | |
| Net Income | (13.5M) | (58.7M) | (149.3M) | (165.2M) | (235.9M) | (247.7M) | |
| Income Tax Expense | (1.3M) | (700K) | (8K) | (2.9M) | (235.9M) | (247.7M) | |
| Net Interest Income | 290K | (340K) | 742K | 2.9M | 7.2M | 7.6M | |
| Interest Income | 290K | 56K | 742K | 2.9M | 7.2M | 7.6M | |
| Net Income From Continuing Ops | (14.9M) | (59.4M) | (149.3M) | (168.1M) | (208.1M) | (197.7M) | |
| Research Development | 11.0M | 45.2M | 121.3M | 142.8M | 210.8M | 221.3M | |
| Reconciled Depreciation | 271K | 700K | 1.1M | 1.7M | 1.7M | 997.5K | |
| Net Income Applicable To Common Shares | (14.9M) | (59.4M) | (149.3M) | (168.1M) | (151.3M) | (143.7M) |
Pair Trading with Dyne Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dyne Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyne Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Dyne Stock
Moving against Dyne Stock
| 0.5 | NXGLW | NexGel Warrant | PairCorr |
| 0.38 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.34 | KZR | Kezar Life Sciences | PairCorr |
| 0.33 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.33 | RNXT | RenovoRx | PairCorr |
The ability to find closely correlated positions to Dyne Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dyne Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dyne Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dyne Therapeutics to buy it.
The correlation of Dyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dyne Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dyne Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dyne Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.58) | Return On Assets (0.40) | Return On Equity (0.69) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.